BR112017000470A2 - composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção - Google Patents
composto, composição farmacêutica, método para modular atividade, método para tratar uma afecçãoInfo
- Publication number
- BR112017000470A2 BR112017000470A2 BR112017000470A BR112017000470A BR112017000470A2 BR 112017000470 A2 BR112017000470 A2 BR 112017000470A2 BR 112017000470 A BR112017000470 A BR 112017000470A BR 112017000470 A BR112017000470 A BR 112017000470A BR 112017000470 A2 BR112017000470 A2 BR 112017000470A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treating
- condition
- pharmaceutical composition
- modulating activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a presente revelação fornece um composto de fórmula (i) e o uso do mesmo para o tratamento terapêutico de cânceres humanos que incluem linfoma de células b-e doenças autoimunes, tais como artrite reumatoide, lúpus eritematoso sistêmico e esclerose múltipla.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021421P | 2014-07-07 | 2014-07-07 | |
| US62/021,421 | 2014-07-07 | ||
| PCT/US2014/061393 WO2016007185A1 (en) | 2014-07-07 | 2014-10-20 | Aminopyridazinone compounds as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017000470A2 true BR112017000470A2 (pt) | 2017-11-07 |
| BR112017000470B1 BR112017000470B1 (pt) | 2022-11-29 |
Family
ID=55064639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017000470-4A BR112017000470B1 (pt) | 2014-07-07 | 2014-10-20 | Compostos, composição farmacêutica e uso do composto ou da composição |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9951077B2 (pt) |
| EP (1) | EP3166608B1 (pt) |
| JP (1) | JP6409116B2 (pt) |
| KR (1) | KR102073797B1 (pt) |
| CN (2) | CN106573001B (pt) |
| AU (1) | AU2014400628B2 (pt) |
| BR (1) | BR112017000470B1 (pt) |
| CA (1) | CA2953798C (pt) |
| ES (1) | ES2706745T3 (pt) |
| MX (1) | MX2017000331A (pt) |
| PL (1) | PL3166608T3 (pt) |
| RU (1) | RU2674701C2 (pt) |
| TW (1) | TWI711619B (pt) |
| WO (1) | WO2016007185A1 (pt) |
| ZA (1) | ZA201700115B (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106573001B (zh) * | 2014-07-07 | 2019-01-29 | 江苏恒瑞医药股份有限公司 | 作为蛋白激酶抑制剂的氨基哒嗪酮化合物 |
| CN105837576B (zh) * | 2015-01-14 | 2019-03-26 | 湖北生物医药产业技术研究院有限公司 | Btk抑制剂 |
| KR20180099787A (ko) * | 2016-01-05 | 2018-09-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Btk 키나아제 억제제의 결정질 형태 및 이의 제조 방법 |
| CN107417687A (zh) * | 2016-05-24 | 2017-12-01 | 中国科学院上海药物研究所 | 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 |
| WO2017202343A1 (zh) * | 2016-05-24 | 2017-11-30 | 中国科学院上海药物研究所 | 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 |
| KR102489537B1 (ko) * | 2016-06-22 | 2023-01-17 | 상하이 포천 파마슈티컬 씨오 엘티디 | 단백질 키나제 억제제로서의 치환된 피롤로[2,3-d]피리다진-4-온 및 피라졸로[3,4-d]피리다진-4-온 |
| WO2018210296A1 (zh) | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 |
| CA3066046A1 (en) | 2017-07-04 | 2019-01-10 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition and method for preparing same |
| WO2019011316A1 (zh) * | 2017-07-14 | 2019-01-17 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的结晶形式及制备方法 |
| MX2020010773A (es) * | 2018-04-13 | 2021-03-02 | Jiangsu Hengrui Medicine Co | Metodo para la preparacion del compuesto de pirroloaminopiridazino na y sus intermedios. |
| US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| KR20210047320A (ko) * | 2018-08-22 | 2021-04-29 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피롤로-아미노-피리다지논 화합물 및 이의 중간체의 제조 방법 |
| CN111499642A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法 |
| TW202100527A (zh) | 2019-05-31 | 2021-01-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種固體分散體及其製備方法 |
| CN110372562B (zh) | 2019-07-09 | 2021-04-06 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂关键中间体的晶型及其制备方法 |
| TW202126640A (zh) * | 2019-09-29 | 2021-07-16 | 大陸商上海森輝醫藥有限公司 | 一種吡咯并胺基噠嗪酮化合物的製備方法 |
| CN112745255A (zh) * | 2019-10-30 | 2021-05-04 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的制备方法 |
| CA3188003A1 (en) | 2020-08-10 | 2022-02-17 | Min Wang | Use of btk inhibitors in the treatment of diseases |
| WO2022042612A1 (zh) * | 2020-08-27 | 2022-03-03 | 上海和誉生物医药科技有限公司 | 二氢吡咯并[2,3-d]哒嗪-7-酮衍生物，其制备方法和应用 |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| CN117355513A (zh) * | 2021-05-21 | 2024-01-05 | 江苏恒瑞医药股份有限公司 | 一种btk抑制剂中间体的制备方法 |
| WO2022261138A1 (en) | 2021-06-08 | 2022-12-15 | Tg Therapeutics, Inc. | Disrupted ikaros signaling as biomarker for btk inhibition |
| WO2023030437A1 (zh) * | 2021-09-01 | 2023-03-09 | 江苏恒瑞医药股份有限公司 | 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途 |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| CN114751850B (zh) * | 2022-06-06 | 2023-08-25 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂关键中间体的制备方法 |
| CN114989062A (zh) * | 2022-07-04 | 2022-09-02 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂中间体的晶型及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5271897B2 (ja) * | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体 |
| CN102887900B (zh) * | 2006-09-22 | 2015-04-29 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| EP2954900A1 (en) | 2007-03-28 | 2015-12-16 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2307025B1 (en) * | 2008-07-16 | 2017-09-20 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| CN102711765A (zh) * | 2009-11-16 | 2012-10-03 | 加利福尼亚大学董事会 | 激酶抑制剂 |
| WO2013113097A1 (en) | 2012-01-31 | 2013-08-08 | Beta Pharma Canada Inc. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
| CA2874211A1 (en) | 2012-05-31 | 2013-12-05 | Pharmascience Inc. | Protein kinase inhibitors |
| JP2015526520A (ja) | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN106573001B (zh) * | 2014-07-07 | 2019-01-29 | 江苏恒瑞医药股份有限公司 | 作为蛋白激酶抑制剂的氨基哒嗪酮化合物 |
-
2014
- 2014-10-20 CN CN201480080486.2A patent/CN106573001B/zh active Active
- 2014-10-20 KR KR1020177002250A patent/KR102073797B1/ko active IP Right Grant
- 2014-10-20 JP JP2017500344A patent/JP6409116B2/ja active Active
- 2014-10-20 ES ES14896967T patent/ES2706745T3/es active Active
- 2014-10-20 US US15/323,929 patent/US9951077B2/en active Active
- 2014-10-20 WO PCT/US2014/061393 patent/WO2016007185A1/en active Application Filing
- 2014-10-20 CN CN201811358086.XA patent/CN109970741B/zh active Active
- 2014-10-20 CA CA2953798A patent/CA2953798C/en active Active
- 2014-10-20 MX MX2017000331A patent/MX2017000331A/es active IP Right Grant
- 2014-10-20 RU RU2017103757A patent/RU2674701C2/ru active
- 2014-10-20 BR BR112017000470-4A patent/BR112017000470B1/pt active IP Right Grant
- 2014-10-20 AU AU2014400628A patent/AU2014400628B2/en active Active
- 2014-10-20 EP EP14896967.8A patent/EP3166608B1/en active Active
- 2014-10-20 PL PL14896967T patent/PL3166608T3/pl unknown
-
2015
- 2015-06-03 TW TW104117984A patent/TWI711619B/zh not_active IP Right Cessation
-
2017
- 2017-01-05 ZA ZA2017/00115A patent/ZA201700115B/en unknown
-
2018
- 2018-02-27 US US15/906,934 patent/US10323037B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109970741B (zh) | 2020-07-28 |
| KR20170023156A (ko) | 2017-03-02 |
| WO2016007185A1 (en) | 2016-01-14 |
| TWI711619B (zh) | 2020-12-01 |
| US20170152264A1 (en) | 2017-06-01 |
| ES2706745T3 (es) | 2019-04-01 |
| EP3166608A1 (en) | 2017-05-17 |
| CN106573001A (zh) | 2017-04-19 |
| ZA201700115B (en) | 2020-05-27 |
| JP2017522302A (ja) | 2017-08-10 |
| AU2014400628A1 (en) | 2017-01-19 |
| US20180251465A1 (en) | 2018-09-06 |
| KR102073797B1 (ko) | 2020-02-05 |
| EP3166608A4 (en) | 2017-11-22 |
| CA2953798A1 (en) | 2016-01-14 |
| EP3166608B1 (en) | 2018-12-12 |
| CA2953798C (en) | 2019-06-11 |
| CN109970741A (zh) | 2019-07-05 |
| JP6409116B2 (ja) | 2018-10-17 |
| RU2674701C2 (ru) | 2018-12-12 |
| TW201625626A (zh) | 2016-07-16 |
| AU2014400628B2 (en) | 2019-05-02 |
| US10323037B2 (en) | 2019-06-18 |
| RU2017103757A (ru) | 2018-08-07 |
| US9951077B2 (en) | 2018-04-24 |
| RU2017103757A3 (pt) | 2018-08-07 |
| MX2017000331A (es) | 2017-08-25 |
| BR112017000470B1 (pt) | 2022-11-29 |
| CN106573001B (zh) | 2019-01-29 |
| PL3166608T3 (pl) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017000470A2 (pt) | composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção | |
| CY1121850T1 (el) | Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων | |
| GEP20207159B (en) | Diacylglycerol acyltransferase 2 inhibitors | |
| CL2016001895A1 (es) | Compuestos | |
| PH12019501097A1 (en) | Magl inhibitors | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| PH12019501102A1 (en) | Magl inhibitors | |
| MY175778A (en) | Heterocyclic compounds and uses thereof | |
| EP4252851A3 (en) | Ezh2 inhibitors for treating lymphoma | |
| JOP20200276A1 (ar) | مثبطات أحادي أسيل جليسرول ليباز (magl) | |
| PH12019501079A1 (en) | Magl inhibitors | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| MX2016015762A (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor. | |
| MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| MX2017013047A (es) | Tratamiento de dolor. | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
| PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
| TW201612183A (en) | Diaryl macrocycles as modulators of protein kinases | |
| MX2018004776A (es) | Compuestos oxaazaespiricos con actividad contral el dolor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: JIANGSU HENGRUI MEDICINE CO., LTD. (CN) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/10/2014, OBSERVADAS AS CONDICOES LEGAIS |